A review of ropinirole prolonged release in Parkinson’s disease

References

• StricklandDBertoniJMParkinson’s prevalence estimated by a state registryMov Disord20041931832315022187
   PubMed Web of Science ®Google Scholar
• TwelvesDPerkinsKSCounsellCSystematic review of incidence studies of Parkinson’s diseaseMov Disord200318193112518297
   PubMed Web of Science ®Google Scholar
• ElbazABowerJHMaraganoreDMRisk tables for parkinsonism and Parkinson’s diseaseJ Clin Epidemiol200255253111781119
   PubMed Web of Science ®Google Scholar
• MiyasakiJMMartinWSuchowerskyOWeinerWJLangAEPractice parameter: initiation of treatment for Parkinson’s disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology200258111711781398
   PubMed Web of Science ®Google Scholar
• GoetzCGPoeweWRascolOSampaioCEvidence-based medical review update: pharmacological and surgical treatments of Parkinson’s disease: 2001 to 2004Mov Disord20052052353915818599
   PubMed Web of Science ®Google Scholar
• HorstinkMTolosaEBonuccelliUReview of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson’s diseaseEur J Neurol2006131170118517038031
   PubMed Web of Science ®Google Scholar
• PahwaRFactorSALyonsKEPractice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology20066698399516606909
   PubMed Web of Science ®Google Scholar
• OlanowCWWattsRLKollerWCAn algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelinesNeurology200156S1S8811402154
   PubMed Web of Science ®Google Scholar
• Parkinson Study GroupLevodopa and the progression of Parkinson’s diseaseN Engl J Med20043512498250815590952
   PubMed Web of Science ®Google Scholar
• ObesoJARodriguez-OrozMCChanaPLeraGRodriguezMOlanowCWThe evolution and origin of motor complications in Parkinson’s diseaseNeurology200055S1320 discussion S21–S13.11147505
   PubMed Web of Science ®Google Scholar
• SchragAQuinnNDyskinesias and motor fluctuations in Parkinson’s disease. A community-based studyBrain2000123(Pt 11)2297230511050029
   PubMed Web of Science ®Google Scholar
• SharmaJCRossINRascolOBrooksDRelationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weightEur J Neurol20081549349618355302
   PubMed Web of Science ®Google Scholar
• OlanowCWRascolOADAGIO InvestigatorsADAGIO: A prospective, double-blind, delayed-start study to examine the potential disease modifying effect of rasagiline in early Parkinson’s diseaseMov Disord2008S194
   Web of Science ®Google Scholar
• RascolOBrooksDJKorczynADDe DeynPPClarkeCELangAEA five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study GroupN Engl J Med20003421484149110816186
   PubMed Web of Science ®Google Scholar
• Parkinson Study GroupPramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trialArch Neurol2004611044105315262734
   PubMed Web of Science ®Google Scholar
• MamikonyanESiderowfADDudaJELong-term follow-up of impulse control disorders in Parkinson’s diseaseMov Disord200823758017960796
   PubMed Web of Science ®Google Scholar
• PhamDQNogidARotigotine transdermal system for the treatment of Parkinson’s diseaseClin Ther20083081382418555929
   PubMed Web of Science ®Google Scholar
• AntoniniAPoeweWFibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s diseaseLancet Neurol2007682682917706566
   PubMed Web of Science ®Google Scholar
• ZanettiniRAntoniniAGattoGGentileRTeseiSPezzoliGValvular heart disease and the use of dopamine agonists for Parkinson’s diseaseN Engl J Med2007356394617202454
   PubMed Web of Science ®Google Scholar
• SnowBJMacdonaldLMcAuleyDWallisWThe effect of amantadine on levodopa-induced dyskinesias in Parkinson’s disease: a double-blind, placebo-controlled studyClin Neuropharmacol200023828510803797
   PubMed Web of Science ®Google Scholar
• Del DottoPPaveseNGambacciniGIntravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled studyMov Disord20011651552011391748
   PubMed Web of Science ®Google Scholar
• WatersCHSethiKDHauserRAMolhoEBertoniJMZydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled studyMov Disord20041942643215077240
   PubMed Web of Science ®Google Scholar
• LeWittPALyonsKEPahwaRAdvanced Parkinson disease treated with rotigotine transdermal system: PREFER StudyNeurology2007681262126717438216
   PubMed Web of Science ®Google Scholar
• DeweyRBJrHuttonJTLeWittPAFactorSAA randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state eventsArch Neurol2001581385139211559309
   PubMed Web of Science ®Google Scholar
• LeopoldNAPolanskyMHurkaMRDrug adherence in Parkinson’s diseaseMov Disord20041951351715133814
   PubMed Web of Science ®Google Scholar
• GrossetDAntoniniACanesiMAdherence to antiparkinson medication in a multicenter European studyMov Disord200923 [Epub ahead of print].
   Web of Science ®Google Scholar
• Requip (ropinirole hydrochloride): US Prescribing Information: Glaxo-SmithKline2006
   Google Scholar
• KayeCMNichollsBClinical pharmacokinetics of ropiniroleClin Pharmacokinet20003924325411069211
   PubMed Web of Science ®Google Scholar
• Requip XL (ropinirole extended release tablets): US Prescribing Information: GlaxoSmithKline2008
   Google Scholar
• TompsonDJVearerDSteady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: Results of two randomized studies in patients with Parkinson’s diseaseClin Ther2007292654266618201581
   PubMed Web of Science ®Google Scholar
• StocchiFHershBPScottBLNausiedaPAGiorgiLRopinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson’s disease: a randomized, double-blind, non-inferiority crossover studyCurr Med Res Opin2008242883289518768106
   PubMed Web of Science ®Google Scholar
• PahwaRStacyMAFactorSARopinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson diseaseNeurology2007681108111517404192
   PubMed Web of Science ®Google Scholar